Fares Jamal, DO; Marian Canon Feliciano, MD; Thomas P. Davis, MD, FACC
The authors describe the feasibility of a hybrid mechanical debulking strategy combining rotational atherectomy and mechanical thrombectomy for treatment of complex lower extremity CTO lesions.
The authors describe the feasibility of a hybrid mechanical debulking strategy combining rotational atherectomy and mechanical thrombectomy for treatment of complex lower extremity CTO lesions.
Drawing on current data and clinical experience, Dr Wilkins highlights the importance of thoughtful patient selection and lesion-specific decision-making to maximize outcomes.
Drawing on current data and clinical experience, Dr Wilkins highlights the importance of thoughtful patient selection and lesion-specific decision-making to maximize outcomes.
Dr Mathews reviews the latest clinical data, discusses evolving techniques, and highlights how retrievable scaffold technology is shaping the future of vascular intervention.
Dr Mathews reviews the latest clinical data, discusses evolving techniques, and highlights how retrievable scaffold technology is shaping the future of vascular intervention.
Tampa, Florida – Concept Medical Inc. (CMI), a global leader in innovative drug-delivery technology across vascular interventions, proudly announces the presentation of the world’s largest randomised controlled trial of a Sirolimus-coated...
Tampa, Florida – Concept Medical Inc. (CMI), a global leader in innovative drug-delivery technology across vascular interventions, proudly announces the presentation of the world’s largest randomised controlled trial of a Sirolimus-coated...
Tom Davis, MD; Peter Dovgan, MD; Eric J. Dippel, MD
This retrospective observational case series evaluated embolic debris retrieval and procedural feasibility of temporary occlusion embolectomy during complex peripheral vascular interventions.
This retrospective observational case series evaluated embolic debris retrieval and procedural feasibility of temporary occlusion embolectomy during complex peripheral vascular interventions.
Dr. Brodmann reviews the results of the TRUE-PTX study, which compared paclitaxel drug-eluting and bare device treatment for PAD using real-world data design.
Dr. Brodmann reviews the results of the TRUE-PTX study, which compared paclitaxel drug-eluting and bare device treatment for PAD using real-world data design.
Dr. Srini Tummala outlines the essential components of a high-quality noninvasive vascular assessment for patients with chronic limb-threatening ischemia.
Dr. Srini Tummala outlines the essential components of a high-quality noninvasive vascular assessment for patients with chronic limb-threatening ischemia.
From redefining what “no-option” truly means, to understanding the role of small artery disease and medial arterial calcification in decision-making, this discussion highlights both clinical data and real-world experience with LimFlow.
From redefining what “no-option” truly means, to understanding the role of small artery disease and medial arterial calcification in decision-making, this discussion highlights both clinical data and real-world experience with LimFlow.
Dr Mathews reviews the latest clinical data, discusses evolving techniques, and highlights how retrievable scaffold technology is shaping the future of vascular intervention.
Dr Mathews reviews the latest clinical data, discusses evolving techniques, and highlights how retrievable scaffold technology is shaping the future of vascular intervention.
Dr. Tepe explores the latest clinical data, emerging innovations, and ongoing challenges shaping the field, offering insight into how DCB technology is redefining endovascular treatment strategies today—and where it may lead.
Dr. Tepe explores the latest clinical data, emerging innovations, and ongoing challenges shaping the field, offering insight into how DCB technology is redefining endovascular treatment strategies today—and where it may lead.
Dr. Brodmann reviews the results of the TRUE-PTX study, which compared paclitaxel drug-eluting and bare device treatment for PAD using real-world data design.
Dr. Brodmann reviews the results of the TRUE-PTX study, which compared paclitaxel drug-eluting and bare device treatment for PAD using real-world data design.
In this video, Clinical Editor Craig Walker, MD, comments on an article from the September issue article entitled “Deep Vein Arterialization for No-Option Chronic Limb-Threatening Ischemia: An Overview of the LimFlow System and CLariTI Study."
In this video, Clinical Editor Craig Walker, MD, comments on an article from the September issue article entitled “Deep Vein Arterialization for No-Option Chronic Limb-Threatening Ischemia: An Overview of the LimFlow System and CLariTI Study."
Mike Watts, MD, FSIR, discusses his presentation on the use of wearables and artificial intelligence in the prevention and treatment of chronic limb-threatening ischemia.
Mike Watts, MD, FSIR, discusses his presentation on the use of wearables and artificial intelligence in the prevention and treatment of chronic limb-threatening ischemia.
Bret N. Wiechmann, MD, FSIR, FAHA; Mike Watts, MD, FSIR
Drs Bret Wiechmann and Mike Watts discuss the differences between hospitals, ambulatory surgery centers, and office-based labs when dealing with CLTI interventions.
Drs Bret Wiechmann and Mike Watts discuss the differences between hospitals, ambulatory surgery centers, and office-based labs when dealing with CLTI interventions.
Michael Pishvaian, MD, PhD, discusses the phase 3 TIGeR-PaC study evaluating intra-arterial gemcitabine among patients with locally advanced pancreatic cancer.
Michael Pishvaian, MD, PhD, discusses the phase 3 TIGeR-PaC study evaluating intra-arterial gemcitabine among patients with locally advanced pancreatic cancer.
Dr Mathews reviews the latest clinical data, discusses evolving techniques, and highlights how retrievable scaffold technology is shaping the future of vascular intervention.
Dr Mathews reviews the latest clinical data, discusses evolving techniques, and highlights how retrievable scaffold technology is shaping the future of vascular intervention.
Dr Costantino outlines practical strategies for identifying appropriate candidates and streamlining procedural workflows in the OBL setting, with a focus on improving efficiency, patient outcomes, and overall practice success.
Dr Costantino outlines practical strategies for identifying appropriate candidates and streamlining procedural workflows in the OBL setting, with a focus on improving efficiency, patient outcomes, and overall practice success.
Dr Salazar examines the current state of venous valve technologies, including recent clinical progress and the challenges that remain before widespread adoption.
Dr Salazar examines the current state of venous valve technologies, including recent clinical progress and the challenges that remain before widespread adoption.
Dr. Tepe explores the latest clinical data, emerging innovations, and ongoing challenges shaping the field, offering insight into how DCB technology is redefining endovascular treatment strategies today—and where it may lead.
Dr. Tepe explores the latest clinical data, emerging innovations, and ongoing challenges shaping the field, offering insight into how DCB technology is redefining endovascular treatment strategies today—and where it may lead.
In this video, renowned cardiovascular and endovascular surgeon Jacques Busquet, MD, from Clinique Val d'Or in Paris, France, explores the mystery of post-EVAR endotension, expanding on insights from his presentation at ISET 2026.
In this video, renowned cardiovascular and endovascular surgeon Jacques Busquet, MD, from Clinique Val d'Or in Paris, France, explores the mystery of post-EVAR endotension, expanding on insights from his presentation at ISET 2026.
Interventional radiologist Sanjay Misra, MD, FSIR, FAHA, FACR, from the Mayo Clinic, highlights key insights from his presentation on renal denervation for hypertension.
Interventional radiologist Sanjay Misra, MD, FSIR, FAHA, FACR, from the Mayo Clinic, highlights key insights from his presentation on renal denervation for hypertension.
Dr. John H. Rundback challenges the long-standing notion that plain balloon angioplasty alone is sufficient for tibial interventions in patients with chronic limb-threatening ischemia .
Dr. John H. Rundback challenges the long-standing notion that plain balloon angioplasty alone is sufficient for tibial interventions in patients with chronic limb-threatening ischemia .
Dr Andrew Holden delivered a comprehensive and forward-looking overview of bioresorbable scaffold technology for BTK disease, with a particular focus on CLTI.
Dr Andrew Holden delivered a comprehensive and forward-looking overview of bioresorbable scaffold technology for BTK disease, with a particular focus on CLTI.
An introduction to the SEPARATE feasibility clinical study of the Clotild Smart Guidewire System (Sensome) in peripheral artery disease was presented at LINC on Tuesday afternoon by Dr Koen Deloose.
An introduction to the SEPARATE feasibility clinical study of the Clotild Smart Guidewire System (Sensome) in peripheral artery disease was presented at LINC on Tuesday afternoon by Dr Koen Deloose.
During Thursday’s “Diagnosis and Imaging in CLTI” session, George Pliagas, MD, FACS, FRCSC, shared how IVUS has reshaped his approach to treating peripheral vascular disease.
During Thursday’s “Diagnosis and Imaging in CLTI” session, George Pliagas, MD, FACS, FRCSC, shared how IVUS has reshaped his approach to treating peripheral vascular disease.
Vascular surgeon Dr. Takahiro Tokuda, from Nagoya Heart Center in Japan, outlines new evidence comparing 2 contemporary revascularization options for heavily calcified femoropopliteal lesions
Vascular surgeon Dr. Takahiro Tokuda, from Nagoya Heart Center in Japan, outlines new evidence comparing 2 contemporary revascularization options for heavily calcified femoropopliteal lesions
Thomas Zeller, MD, from the Universitaets-Herzzentrum Freiburg, Bad Krozingen, Germany, presented the inaugural findings from the WOUND infection and clinical outcomeS IN patients with Chronic Limb-Threatening Ischemia (WOUNDSinCLTI) study,
Thomas Zeller, MD, from the Universitaets-Herzzentrum Freiburg, Bad Krozingen, Germany, presented the inaugural findings from the WOUND infection and clinical outcomeS IN patients with Chronic Limb-Threatening Ischemia (WOUNDSinCLTI) study,
Mike Watts, MD, FSIR, from Atlantic Medical Imaging in New Jersey, presented a practical, real-world approach to performing distal deep venous arterialization (dDVA) in the office-based lab.
Mike Watts, MD, FSIR, from Atlantic Medical Imaging in New Jersey, presented a practical, real-world approach to performing distal deep venous arterialization (dDVA) in the office-based lab.
During a Wednesday afternoon session at ISET 2026, Sr William Kuo walked attendees through a practical, case-based approach to managing inferior vena cava thrombosis.
During a Wednesday afternoon session at ISET 2026, Sr William Kuo walked attendees through a practical, case-based approach to managing inferior vena cava thrombosis.
Dr. John H. Rundback challenges the long-standing notion that plain balloon angioplasty alone is sufficient for tibial interventions in patients with chronic limb-threatening ischemia .
Dr. John H. Rundback challenges the long-standing notion that plain balloon angioplasty alone is sufficient for tibial interventions in patients with chronic limb-threatening ischemia .
Sean P. Lyden, MD, discussed new real-world data from the PROWL Registry, offering a look at how acute, subacute, and CLTI are being treated outside the confines of traditional clinical trial exclusions.
Sean P. Lyden, MD, discussed new real-world data from the PROWL Registry, offering a look at how acute, subacute, and CLTI are being treated outside the confines of traditional clinical trial exclusions.
Dr Andrew Holden delivered a comprehensive and forward-looking overview of bioresorbable scaffold technology for BTK disease, with a particular focus on CLTI.
Dr Andrew Holden delivered a comprehensive and forward-looking overview of bioresorbable scaffold technology for BTK disease, with a particular focus on CLTI.
Nicos Labropoulos, MD, presented an overview of what defines a “high-risk” carotid plaque and why relying on luminal stenosis alone is no longer enough.
Nicos Labropoulos, MD, presented an overview of what defines a “high-risk” carotid plaque and why relying on luminal stenosis alone is no longer enough.
Tampa, Florida – Concept Medical Inc. (CMI), a global leader in innovative drug-delivery technology across vascular interventions, proudly announces the presentation of the world’s largest randomised controlled trial of a Sirolimus-coated...
Tampa, Florida – Concept Medical Inc. (CMI), a global leader in innovative drug-delivery technology across vascular interventions, proudly announces the presentation of the world’s largest randomised controlled trial of a Sirolimus-coated...
JANUARY 8, 2026 –HOUMA, LA – Cardiovascular Institute of the South (CIS) and Terrebonne General Health System (Terrebonne General) are the first in Louisiana to use the AngioSafe Santreva™-ATK Endovascular Revascularization Catheter to...
JANUARY 8, 2026 –HOUMA, LA – Cardiovascular Institute of the South (CIS) and Terrebonne General Health System (Terrebonne General) are the first in Louisiana to use the AngioSafe Santreva™-ATK Endovascular Revascularization Catheter to...
The study will evaluate the safety and effectiveness of the Artero™ IVL system in treating peripheral arterial disease (PAD) and support FastWave's ultimate path to FDA clearance.
The study will evaluate the safety and effectiveness of the Artero™ IVL system in treating peripheral arterial disease (PAD) and support FastWave's ultimate path to FDA clearance.
JUNE 16, 2025 – HOUMA, LA – Cardiovascular Institute of the South (CIS) and Terrebonne General Health System (Terrebonne General) are the first in Louisiana to use the Spur® Peripheral Retrievable Stent System to treat chronic...
JUNE 16, 2025 – HOUMA, LA – Cardiovascular Institute of the South (CIS) and Terrebonne General Health System (Terrebonne General) are the first in Louisiana to use the Spur® Peripheral Retrievable Stent System to treat chronic...
NEW ORLEANS, LA, JUNE 6, 2025 – A large retrospective review of over 100,000 patients found the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in moderate peripheral artery disease (PAD) is associated with a decreased rate of...
NEW ORLEANS, LA, JUNE 6, 2025 – A large retrospective review of over 100,000 patients found the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in moderate peripheral artery disease (PAD) is associated with a decreased rate of...
May 24, 2024 – Lafayette, LA – Cardiovascular Institute of the South (CIS) is the first in the world to use the 200-cm RANGER Drug-Coated Balloon to treat peripheral artery disease (PAD) in the legs. CIS interventional cardiologist Dr....
May 24, 2024 – Lafayette, LA – Cardiovascular Institute of the South (CIS) is the first in the world to use the 200-cm RANGER Drug-Coated Balloon to treat peripheral artery disease (PAD) in the legs. CIS interventional cardiologist Dr....
The first patient in its ELITE-BTK pivotal trial was treated by Dr. Brian DeRubertis, FACS, Chief of the Division of Vascular & Endovascular Surgery at NewYork-Presbyterian and Weill Cornell Medicine in New York City.
The first patient in its ELITE-BTK pivotal trial was treated by Dr. Brian DeRubertis, FACS, Chief of the Division of Vascular & Endovascular Surgery at NewYork-Presbyterian and Weill Cornell Medicine in New York City.
Bloomington, Ind. — Cook Medical’s Zilver PTX drug-eluting stent (DES) has lower rates of in-stent occlusions among patients with restenosis at 3 years than Boston Scientific’s Eluvia DES, according to real-world data from the REALDES study....
Bloomington, Ind. — Cook Medical’s Zilver PTX drug-eluting stent (DES) has lower rates of in-stent occlusions among patients with restenosis at 3 years than Boston Scientific’s Eluvia DES, according to real-world data from the REALDES study....
The Auryon laser can be used to treat all infrainguinal lesion types, including above-the-knee (ATK), below-the-knee (BTK) and In-Stent Restenosis (ISR)3-6 and to date, it has been used to treat more than 100,000 patients7 in the United...
The Auryon laser can be used to treat all infrainguinal lesion types, including above-the-knee (ATK), below-the-knee (BTK) and In-Stent Restenosis (ISR)3-6 and to date, it has been used to treat more than 100,000 patients7 in the United...
Eric A. Secemsky, MD, MSc, lead investigator for the ELITE-BTK pivotal trial, said, “R3 Vascular’s novel approach in the design of its next generation bioresorbable drug eluting scaffold is of great interest to the physician community and has...
Eric A. Secemsky, MD, MSc, lead investigator for the ELITE-BTK pivotal trial, said, “R3 Vascular’s novel approach in the design of its next generation bioresorbable drug eluting scaffold is of great interest to the physician community and has...
Tempe, AZ – June 25, 2026 – Nectero Therapeutics announced today a first-in-human (FIH) multicenter study evaluated treatment of small- to medium-sized abdominal aortic aneurysms (AAA) with pentagalloylglucose (PGG) using its investigational...
Tempe, AZ – June 25, 2026 – Nectero Therapeutics announced today a first-in-human (FIH) multicenter study evaluated treatment of small- to medium-sized abdominal aortic aneurysms (AAA) with pentagalloylglucose (PGG) using its investigational...
Key Highlights
The Volante Steerable Guiding Sheath is designed to facilitate intracardiac, renal and peripheral placement of diagnostic and therapeutic devices.
With five different lengths and six different French sizes,...
Key Highlights
The Volante Steerable Guiding Sheath is designed to facilitate intracardiac, renal and peripheral placement of diagnostic and therapeutic devices.
With five different lengths and six different French sizes,...
Treating patients within 12 hours of diagnosis may be associated with greater improvement in acute hemodynamic and right ventricle measures compared to treatment after 12 hours, with similar safety outcomes between groups.
Treating patients within 12 hours of diagnosis may be associated with greater improvement in acute hemodynamic and right ventricle measures compared to treatment after 12 hours, with similar safety outcomes between groups.
The most notable enhancement is the ability to view medical images directly within the app. This long-awaited feature enables care teams to review imaging in real time.
The most notable enhancement is the ability to view medical images directly within the app. This long-awaited feature enables care teams to review imaging in real time.
The THUNDERBOLT™ Computer Assisted Vacuum Thrombectomy (CAVT™) technology introduces modulated aspiration for acute ischemic stroke for the first time, enabling more rapid, complete clot removal.
The THUNDERBOLT™ Computer Assisted Vacuum Thrombectomy (CAVT™) technology introduces modulated aspiration for acute ischemic stroke for the first time, enabling more rapid, complete clot removal.
Powered by the Penumbra ENGINE™, THUNDERBOLT introduces modulated aspiration to Penumbra’s neuro thrombectomy portfolio, offering advanced CAVT technology designed to detect, fatigue, and completely ingest clot at the site of the occlusion.
Powered by the Penumbra ENGINE™, THUNDERBOLT introduces modulated aspiration to Penumbra’s neuro thrombectomy portfolio, offering advanced CAVT technology designed to detect, fatigue, and completely ingest clot at the site of the occlusion.
New Britain, PA, June 15, 2026 – Thrombolex, Inc., a commercial-stage medical device company advancing a differentiated pharmaco-mechanical lysis (PML) platform for the treatment of pulmonary embolism (PE) and other thromboembolic diseases,...
New Britain, PA, June 15, 2026 – Thrombolex, Inc., a commercial-stage medical device company advancing a differentiated pharmaco-mechanical lysis (PML) platform for the treatment of pulmonary embolism (PE) and other thromboembolic diseases,...
“Our study was designed to establish the evidence of a comprehensive multidisciplinary approach before considering surgical intervention,” said Dr. Richard Shi, vascular surgery resident at the Medical University of South Carolina. “Too...
“Our study was designed to establish the evidence of a comprehensive multidisciplinary approach before considering surgical intervention,” said Dr. Richard Shi, vascular surgery resident at the Medical University of South Carolina. “Too...
"The V-PULSE system removed significant clot burden and provided immediate visual confirmation of thrombus capture through its integrated filtration technology," said Makmood Razavi, MD.
"The V-PULSE system removed significant clot burden and provided immediate visual confirmation of thrombus capture through its integrated filtration technology," said Makmood Razavi, MD.
